866-997-4948(US-Canada Toll Free)

Irritable Bowel Syndrome - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : May 2017

Category :

Pharmaceutical

No. of Pages : 148 Pages

Irritable Bowel Syndrome - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Irritable Bowel Syndrome - Pipeline Review, H1 2017, provides an overview of the Irritable Bowel Syndrome (Gastrointestinal) pipeline landscape.

Inflammatory Bowel Diseases (IBD) is a broad term that describes conditions with chronic or recurring immune response and inflammation of the gastrointestinal tract. Signs and symptoms include abdominal cramps and pain, diarrhea that may be bloody, weight loss, loss of appetite and fever. The predisposing factors include age, family history, smoking and some pain killers. Treatment includes corticosteroids, immune suppressors, antibiotics and pain relievers.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Irritable Bowel Syndrome - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Irritable Bowel Syndrome (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Irritable Bowel Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 12, 7, 11 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Irritable Bowel Syndrome (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Irritable Bowel Syndrome (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Irritable Bowel Syndrome (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Irritable Bowel Syndrome (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Irritable Bowel Syndrome (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Irritable Bowel Syndrome - Overview 8
Irritable Bowel Syndrome - Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 13
Products under Development by Companies 14
Products under Development by Universities/Institutes 16
Irritable Bowel Syndrome - Therapeutics Assessment 17
Assessment by Target 17
Assessment by Mechanism of Action 20
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Irritable Bowel Syndrome - Companies Involved in Therapeutics Development 27
4D Pharma PLC 27
A. Menarini Industrie Farmaceutiche Riunite Srl 27
Alfa Wassermann SpA 28
Allergan Plc 28
Ardelyx Inc 29
Astellas Pharma Inc 29
CJ HealthCare Corp 30
ConSynance Therapeutics Inc 30
Cosmo Pharmaceuticals NV 31
Dong-A ST Co., Ltd. 31
Eisai Co Ltd 32
Enterome Bioscience SA 32
GlaxoSmithKline Plc 33
Innovative Med Concepts LLC 33
Ironwood Pharmaceuticals Inc 34
Kissei Pharmaceutical Co Ltd 35
Lexicon Pharmaceuticals Inc 35
Napo Pharmaceuticals Inc 36
Pfizer Inc 36
RaQualia Pharma Inc 37
RedHill Biopharma Ltd 37
SK Biopharmaceuticals Co Ltd 38
Sumitomo Dainippon Pharma Co Ltd 38
Synergy Pharmaceuticals Inc 39
Synthetic Biologics Inc 39
Vitality Biopharma Inc 40
Irritable Bowel Syndrome - Drug Profiles 41
(celecoxib + famciclovir) - Drug Profile 41
ASP-7147 - Drug Profile 43
bedoradrine sulfate - Drug Profile 44
Biologic for Irritable Bowel Syndrome with Constipation - Drug Profile 47
Biologic for Irritable Bowel Syndrome with Diarrhea - Drug Profile 48
Blautix - Drug Profile 49
Canchew Plus - Drug Profile 51
CJ-14199 - Drug Profile 52
crofelemer DR - Drug Profile 53
CSTI-300 - Drug Profile 57
DA-6886 - Drug Profile 58
Drugs for Irritable Bowel Syndrome with Diarrhea - Drug Profile 59
DSP-6952 - Drug Profile 60
E-2508 - Drug Profile 61
EB-420 - Drug Profile 62
GSK-3179106 - Drug Profile 63
ibodutant - Drug Profile 64
linaclotide - Drug Profile 65
linaclotide DR1 - Drug Profile 73
linaclotide DR2 - Drug Profile 74
lovastatin - Drug Profile 75
LT-4006 - Drug Profile 79
LX-1033 - Drug Profile 80
ondansetron hydrochloride CR - Drug Profile 82
ORP-101 - Drug Profile 88
PBF-677 - Drug Profile 89
plecanatide - Drug Profile 90
PR-38 - Drug Profile 99
pregabalin - Drug Profile 100
relenopride hydrochloride - Drug Profile 105
rifamycin CR - Drug Profile 107
rifaximin - Drug Profile 110
RQ-00202730 - Drug Profile 114
RQ-00310941 - Drug Profile 115
Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for IBS and Migraine - Drug Profile 116
solabegron hydrochloride - Drug Profile 117
tenapanor hydrochloride - Drug Profile 120
VB-210 - Drug Profile 125
Irritable Bowel Syndrome - Dormant Projects 126
Irritable Bowel Syndrome - Discontinued Products 129
Irritable Bowel Syndrome - Product Development Milestones 130
Featured News & Press Releases 130
Appendix 145
Methodology 145
Coverage 145
Secondary Research 145
Primary Research 145
Expert Panel Validation 145
Contact Us 145
Disclaimer 146

List of Tables
Number of Products under Development for Irritable Bowel Syndrome, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Irritable Bowel Syndrome - Pipeline by 4D Pharma PLC, H1 2017
Irritable Bowel Syndrome - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2017
Irritable Bowel Syndrome - Pipeline by Alfa Wassermann SpA, H1 2017
Irritable Bowel Syndrome - Pipeline by Allergan Plc, H1 2017
Irritable Bowel Syndrome - Pipeline by Ardelyx Inc, H1 2017
Irritable Bowel Syndrome - Pipeline by Astellas Pharma Inc, H1 2017
Irritable Bowel Syndrome - Pipeline by CJ HealthCare Corp, H1 2017
Irritable Bowel Syndrome - Pipeline by ConSynance Therapeutics Inc, H1 2017
Irritable Bowel Syndrome - Pipeline by Cosmo Pharmaceuticals NV, H1 2017
Irritable Bowel Syndrome - Pipeline by Dong-A ST Co., Ltd., H1 2017
Irritable Bowel Syndrome - Pipeline by Eisai Co Ltd, H1 2017
Irritable Bowel Syndrome - Pipeline by Enterome Bioscience SA, H1 2017
Irritable Bowel Syndrome - Pipeline by GlaxoSmithKline Plc, H1 2017
Irritable Bowel Syndrome - Pipeline by Innovative Med Concepts LLC, H1 2017
Irritable Bowel Syndrome - Pipeline by Ironwood Pharmaceuticals Inc, H1 2017
Irritable Bowel Syndrome - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2017
Irritable Bowel Syndrome - Pipeline by Lexicon Pharmaceuticals Inc, H1 2017
Irritable Bowel Syndrome - Pipeline by Napo Pharmaceuticals Inc, H1 2017
Irritable Bowel Syndrome - Pipeline by Pfizer Inc, H1 2017
Irritable Bowel Syndrome - Pipeline by RaQualia Pharma Inc, H1 2017
Irritable Bowel Syndrome - Pipeline by RedHill Biopharma Ltd, H1 2017
Irritable Bowel Syndrome - Pipeline by SK Biopharmaceuticals Co Ltd, H1 2017
Irritable Bowel Syndrome - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017
Irritable Bowel Syndrome - Pipeline by Synergy Pharmaceuticals Inc, H1 2017
Irritable Bowel Syndrome - Pipeline by Synthetic Biologics Inc, H1 2017
Irritable Bowel Syndrome - Pipeline by Vitality Biopharma Inc, H1 2017
Irritable Bowel Syndrome - Dormant Projects, H1 2017
Irritable Bowel Syndrome - Dormant Projects, H1 2017 (Contd..1), H1 2017
Irritable Bowel Syndrome - Dormant Projects, H1 2017 (Contd..2), H1 2017
Irritable Bowel Syndrome - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Irritable Bowel Syndrome, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *